Comparative Pharmacology
Head-to-head clinical analysis: IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE versus VIVLODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE versus VIVLODEX.
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE vs VIVLODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. Diphenhydramine is an antihistamine that antagonizes histamine H1 receptors.
COX-2 inhibitor; reduces prostaglandin synthesis via inhibition of cyclooxygenase-2 (COX-2) with minimal COX-1 inhibition.
1-2 tablets (200 mg ibuprofen/25 mg diphenhydramine HCl each) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours.
Once daily oral administration of 100 mg or 200 mg capsules. The recommended dose is 100 mg once daily; dose may be increased to 200 mg once daily if response is inadequate. Maximum daily dose: 200 mg.
None Documented
None Documented
Ibuprofen: 2-4 hours (immediate-release). Diphenhydramine: 8-12 hours (prolonged in hepatic impairment).
Terminal elimination half-life of the active moiety meloxicam is approximately 20 hours (range 12-24 h), allowing once-daily dosing in chronic pain.
Ibuprofen: Renal (90% as glucuronide conjugates, <10% unchanged). Diphenhydramine: Renal (primarily as metabolites, <10% unchanged). Both undergo hepatic metabolism with renal excretion of metabolites.
VIVLODEX is a meloxicam NSAID prodrug. Following hydrolysis to meloxicam, excretion is primarily hepatic (metabolism) and renal (urine). Approximately 50% of meloxicam dose is excreted in urine as metabolites and <5% as parent drug; about 40% in feces. Biliary excretion is minor.
Category D/X
Category C
NSAID
NSAID